Midomafetamine for substance-related disorders

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Also followed for narrower conditions: Alcoholism

Why this status

  1. 30 Mar 2023: Trial registered, NCT05790239
  2. 1 Mar 2025: Trial started, NCT05790239

The trials

NCT05790239: MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder

State
Under way
Phase
Phase 2
People
40 planned
Started
1 Mar 2025
Primary completion
Mar 2028
Arms
MDMA-Assisted Therapy
Results
None posted
  1. 30 Mar 2023: Trial registered
  2. 1 Mar 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as 3,4 Methylenedioxymethamphetamine, 3,4-Methylenedioxymethamphetamine (MDMA), 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxymethamphetamine (125 mg), Active Dose 1 (125 mg) MDMA HCl, Active Dose 2 (100 mg) MDMA HCl, Full Dose MDMA, Full Dose MDMA-assisted therapy (125 mg), Full dose MDMA-assisted therapy, Mdma, MDMA assisted psychotherapy, Open-Label Full Dose MDMA-assisted therapy (125 mg), methylenedioxymethamphetamine.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.